Seattle genetics & astellas receive fda breakthrough therapy designation for padcev in combination with pembrolizumab in 1st-line advanced bladder cancer

Seattle genetics and astellas receive fda breakthrough therapy designation for padcev™ (enfortumab vedotin-ejfv) in combination with pembrolizumab in first-line advanced bladder cancer.seattle genetics inc - breakthrough therapy designation based on initial results from phase 1b/2 ev-103 clinical trial.seattle genetics inc - granted breakthrough therapy designation for padcev in combination with merck's anti-pd-1 therapy keytruda.
SGEN Ratings Summary
SGEN Quant Ranking